Semaglutide Side Effects Across Every Brand, From the FDA Labels

    Short answer

    Semaglutide is the active ingredient in Ozempic and Rybelsus for type 2 diabetes and in Wegovy for weight management, heart risk reduction and, for the injection, a liver condition called MASH with moderate to advanced fibrosis. On every one of their FDA labels, nausea, diarrhea, vomiting, constipation and stomach pain are among the most common side effects.

    Three brands, one ingredient, the same leading effects. This guide compares the trial numbers from each label and the Rybelsus figures, then points to the full Ozempic and Wegovy guides for the serious warnings and when to get help. Sources are the Ozempic label revised May 2026, the Wegovy label revised June 2026 and the Rybelsus label revised January 2026. It is general information, not medical advice, and Pep AI is not affiliated with Novo Nordisk.

    The Big Picture in Four Lines

    Sources: the Ozempic (05/2026), Wegovy (06/2026) and Rybelsus (01/2026) prescribing information.

    Nausea Leads on Every Label

    Nausea was reported by 11% to 20% of people on Rybelsus, about 16% to 20% on Ozempic and 44% on the Wegovy 2.4 mg injection. Each trial had its own population and dose, so these ranges describe each label rather than rank the brands.

    Dose Increases Are the Common Trigger

    All three labels say most nausea, vomiting and diarrhea happened during dose escalation. That is why some people notice the weeks after a step-up more than the weeks in between.

    Most People Kept Taking It

    Stopping because of stomach effects ranged from about 3% to 4% on Ozempic to 4% to 8% on Rybelsus. Placebo rates in those trials were about 1% or lower.

    The Same Boxed Warning Applies

    Every semaglutide label carries a boxed warning about thyroid C-cell tumors seen in rodents. Pancreatitis, gallbladder disease, kidney injury and allergic reactions also appear on each one.

    Ozempic, Wegovy and Rybelsus Compared

    One row per brand and form. The doses are the label's trial arms, not a recommendation, and rates from different trials cannot be directly compared.

    BrandFormApproved usesNauseaAny stomach effectPlacebo (nausea / stomach)
    OzempicWeekly injectionType 2 diabetes, including heart and kidney risk reduction15.8% to 20.3%33% to 36%6.1% / 15%
    WegovyWeekly injection (2.4 mg trials)Weight management, heart risk reduction, MASH with moderate to advanced fibrosis44%73%16% / 47%
    WegovyDaily tablet (25 mg trial)Weight management, heart risk reductionSimilar to the injectionSimilar to the injectionNot compared here
    Rybelsus (and Ozempic tablets)Daily tabletType 2 diabetes, including heart risk reduction11% to 20%32% to 41%6% / 21%

    Ozempic Injection

    In placebo-controlled trials in adults with type 2 diabetes, nausea was reported by 15.8% to 20.3% of people on Ozempic versus 6.1% on placebo. Any stomach effect was reported by about 33% to 36%, compared with about 15%.

    Wegovy Injection and Tablet

    On the weekly 2.4 mg injection, nausea was reported by 44% of adults and any stomach effect by 73%, compared with 16% and 47% on placebo. The label says the 25 mg daily tablet showed similar types and frequency of common side effects.

    Rybelsus Tablet

    In the Rybelsus trials in adults with type 2 diabetes, nausea was reported by 11% to 20% versus 6% on placebo. Any stomach effect was reported by 32% to 41%, compared with 21%.

    Why the Rates Are Not a Ranking

    The Wegovy trials enrolled adults with obesity or overweight at a higher dose, while the Ozempic and Rybelsus trials enrolled adults with type 2 diabetes. The labels note that rates from different trials cannot be directly compared.

    Brand-by-Brand Detail

    For the full Ozempic table, read Ozempic side effects. For the injection and tablet data on the weight management brand, read Wegovy side effects.

    Other Effects That Show Up on the Labels

    On Rybelsus, stomach pain was reported by 10% to 11% of people versus 4% on placebo, and decreased appetite by 6% to 9% versus 1%. Indigestion, gas, reflux and gastritis appear on all three labels at lower rates. The injection figures for other effects are in Ozempic side effects and Wegovy side effects.

    Rybelsus side effectRybelsusPlacebo
    Stomach pain10% to 11%4%
    Decreased appetite6% to 9%1%

    Serious Warnings Shared Across Brands

    Every semaglutide label carries a boxed warning about thyroid C-cell tumors seen in rodents, and none should be used with a personal or family history of medullary thyroid carcinoma or MEN 2. The labels also warn about pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar with insulin or a sulfonylurea, serious allergic reactions and aspiration during anesthesia. The full warnings for each brand are in Ozempic side effects and Wegovy side effects.

    When to Call or Seek Emergency Care

    Swelling of the face, lips, tongue or throat, trouble breathing, or severe stomach pain that will not go away need emergency care. Call your prescriber about vomiting or diarrhea that does not ease, signs of dehydration, vision changes, symptoms of low blood sugar, or upper stomach pain with fever, yellowing of the skin or eyes, or clay-colored stools. Each brand's full list is in Ozempic side effects and Wegovy side effects.

    This is not a complete list and it is not medical advice: if something feels wrong, call.

    From the makers of this guide

    Follow Your Own Pattern, Whatever the Brand

    Pep AI lets you rate symptoms such as nausea, constipation, headache, fatigue and injection-site pain for severity each day, from a built-in list of GLP-1 symptoms grouped by body area, plus your own. A daily check-in adds mood, energy and sleep quality. For weekly Ozempic or Wegovy shots, your side-effect trend sits next to the estimated level chart on the Dose tab.

    1. 01

      Symptoms Rated by Severity

      Pick from the built-in list or add your own, and rate how strong each one was that day.

    2. 02

      Side-effect trend on the Dose tab

      Your symptom trend over recent days, on the same tab as your logged doses.

    3. 03

      Estimated level chart for weekly shots

      For weekly Ozempic or Wegovy shots, an estimate from your logged doses and the label half-life, not a lab value. It is not built for daily tablets.

    Download on the App StoreGet it on Google Play

    Share What You Logged With Your Prescriber

    Pep AI creates a PDF report of your full history, including your doses and weight. Show it at the appointment or send it ahead, and for the symptoms worth raising, see Ozempic side effects or Wegovy side effects.

    Key takeaways

    • Nausea was reported by 11% to 20% on Rybelsus, about 16% to 20% on Ozempic and 44% on the Wegovy 2.4 mg injection.
    • All three labels say most nausea, vomiting and diarrhea happened during dose escalation.
    • The Wegovy label says its 25 mg tablet showed similar types and frequency of common side effects to the injection.
    • Every semaglutide label carries the boxed thyroid C-cell tumor warning; the Ozempic and Wegovy guides hold the full warnings.
    • The trials enrolled different people at different doses, so the rates cannot be directly compared.

    Know which side effects are yours.

    Pep AI logs your semaglutide shots or tablets, symptoms with severity, meals and weight, and makes a PDF of your doses, injection sites and weight. Download Pep AI on iPhone or Android.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Ozempic (semaglutide) injection prescribing information and Medication Guide, Novo Nordisk / FDA (revised 05/2026)
    2. Wegovy (semaglutide) injection and tablets prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
    3. Rybelsus and Ozempic tablets (semaglutide) prescribing information and Medication Guide, Novo Nordisk / FDA (revised 01/2026)
    4. MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    This page summarizes the Ozempic (revised 05/2026), Wegovy (revised 06/2026) and Rybelsus and Ozempic tablets (revised 01/2026) prescribing information for semaglutide. It is general information, not medical advice, and does not replace your prescriber or pharmacist. Rates from different trials cannot be directly compared. Pep AI is not affiliated with or endorsed by Novo Nordisk. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026